EKSO BIONICS (EKSO) AI Stock Analysis

• Market Cap: $17.40M
• Dividend Yield: N/A
• Average Volume (3M): 56.84K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.83
• Revenue Growth: -16.59%
• EPS Growth: 43.20%
• Country: US
• Employees: 61
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.54
• Shares Outstanding: 3,392,723
• 10 Day Avg. Volume: 46,910
• 30 Day Avg. Volume: 56,843
• PEG Ratio: 0.33
• Price to Book (P/B): 14.52
• Price to Sales (P/S): 10.29
• P/FCF Ratio: -18.67
• Enterprise Value/Market Cap: 0.42
• Enterprise Value/Revenue: 0.50
• Enterprise Value/Gross Profit: 0.93
• Enterprise Value/Ebitda: -0.75
• 1Y Price Target: $6.00
• Price Target Upside: 30.43% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $5.00 ▲(8.70% Upside)

EKSO BIONICS' overall stock score is primarily impacted by its financial performance, which shows significant challenges with profitability and cash flow. The technical analysis suggests a bearish trend, while the valuation is weakened by a negative P/E ratio and lack of dividend yield. These factors collectively indicate a cautious outlook for the stock.

Positive Factors

Product Innovation

EKSO's focus on innovative exoskeleton technology positions it well in the growing rehabilitation and industrial sectors, enhancing long-term growth potential.

Gross Profit Margin Improvement

Improved gross profit margins indicate better cost control and operational efficiency, which can lead to enhanced profitability over time.

Moderate Leverage

Moderate leverage suggests a balanced approach to financing, providing flexibility for future investments and stability in financial operations.

Negative Factors

Negative Profitability

Persistent negative profitability highlights ongoing challenges in achieving sustainable earnings, which could impact long-term financial health.

Reliance on External Financing

Dependence on external financing for cash flow needs can limit operational flexibility and increase financial risk if market conditions change.

Negative Return on Equity

A negative return on equity indicates inefficiency in generating returns on shareholders' investments, which may deter potential investors.

EKSO BIONICS Business Overview & Revenue Model

Company Description

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.

How the Company Makes Money

EKSO BIONICS generates revenue through several key streams, primarily from the sale and leasing of its exoskeleton devices to healthcare facilities and industrial clients. The company also earns money through service contracts, which include maintenance, training, and support for its products. Additionally, EKSO may benefit from partnerships with rehabilitation centers and industrial organizations that integrate their technology into existing workflows. Grants and funding from governmental and private research initiatives can also contribute to their revenue, particularly in the development of new technologies and applications for their exoskeleton systems.

EKSO BIONICS Financial Statement Overview

Summary

EKSO BIONICS faces ongoing financial challenges characterized by negative profitability and cash flow metrics. While there are signs of improvement in operational efficiency and cash flow management, the company needs to address its persistent losses and reliance on external financing. The moderate leverage and stable equity position offer some stability, yet achieving consistent revenue growth and profitability remains crucial for long-term sustainability.

Income Statement

EKSO BIONICS has shown a volatile revenue trajectory with a slight revenue decline of 1.94% from 2023 to 2024. The gross profit margin improved to 53.06% in 2024 from 49.68% in 2023, indicating efficiency in controlling direct costs. However, the company continues to face challenges with profitability, as evidenced by a negative net profit margin of -63.21% in 2024, despite improving from -83.17% in 2023. The EBIT and EBITDA margins remain negative, reflecting ongoing operational challenges.

Balance Sheet

EKSO BIONICS' balance sheet reflects a stable equity position with an equity ratio of 47.68% as of 2024. The debt-to-equity ratio stands at 0.47, indicating moderate leverage, which has slightly decreased from 0.57 in 2023. However, the return on equity remains negative at -89.17% due to persistent net losses, highlighting a challenging environment for shareholder returns.

Cash Flow

The cash flow statement reveals a negative free cash flow for 2024, although it improved by 19.46% compared to 2023. The operating cash flow to net income ratio is 0.87, suggesting that operational cash generation is not sufficient to cover net losses. The company is heavily reliant on financing activities to support cash flow needs.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	14.75M	17.93M	18.28M	12.91M	11.25M	8.88M
Gross Profit	7.89M	9.51M	9.08M	6.21M	6.75M	5.07M
EBITDA	-9.70M	-9.45M	-13.20M	-14.04M	-9.09M	-15.07M
Net Income	-10.43M	-11.33M	-15.20M	-15.08M	-9.76M	-15.82M
Balance Sheet
Total Assets	21.66M	26.65M	28.92M	40.90M	49.17M	20.60M
Cash, Cash Equivalents and Short-Term Investments	2.72M	6.49M	8.64M	20.52M	40.41M	12.86M
Total Debt	3.02M	5.98M	7.17M	7.50M	2.22M	3.86M
Total Liabilities	11.98M	13.95M	16.31M	15.46M	11.95M	16.16M
Stockholders Equity	9.68M	12.71M	12.61M	25.44M	37.22M	4.43M
Cash Flow
Free Cash Flow	-8.87M	-9.88M	-12.21M	-14.88M	-11.21M	-8.76M
Operating Cash Flow	-8.90M	-9.85M	-12.05M	-14.69M	-11.16M	-8.76M
Investing Cash Flow	-83.00K	-37.00K	-157.00K	-5.17M	-59.00K	0.00
Financing Cash Flow	3.39M	7.77M	348.00K	0.00	38.71M	10.70M

EKSO BIONICS Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 4.60
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EKSO, the sentiment is Neutral. The current price of 4.6 is below the 20-day moving average (MA) of 4.60, below the 50-day MA of 4.87, and below the 200-day MA of 4.96, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 49.63 is Neutral, neither overbought nor oversold. The STOCH value of 88.02 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for EKSO.

EKSO BIONICS Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HBIO	56 Neutral	$34.13M	―	-135.62%	―	-10.60%	-271.93%
MHUA	55 Neutral	$7.27M	42.41	5.90%	―	-4.99%	-19.11%
EKSO	53 Neutral	$17.40M	-0.92	-85.01%	―	-16.59%	43.20%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MLSS	41 Neutral	$29.73M	-4.35	-136.47%	―	0.59%	-39.76%
POAI	38 Underperform	$30.36M	-0.34	―	―	-47.20%	-163.72%
LUCY	35 Underperform	$7.18M	-0.48	-74.10%	―	53.22%	72.69%

EKSO BIONICS Corporate Events

Ekso Bionics Announces Executive Equity Award Grants

On November 5, 2025, Ekso Bionics Holdings, Inc. announced equity award grants to executives Scott Davis, Jerome Wong, and Jason Jones to motivate stockholder growth and achieve strategic goals. The grants include restricted stock units and phantom performance-based RSUs, with specific vesting conditions tied to company performance metrics. Additionally, the company entered into Change in Control and Severance Agreements with these executives, outlining severance benefits in case of employment termination under certain conditions, which may impact the company’s financial obligations and executive retention strategies.

The most recent analyst rating on (EKSO) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on EKSO BIONICS stock, see the EKSO Stock Forecast page.

Ekso Bionics Announces $3.2 Million Stock Offering

On October 28, 2025, Ekso Bionics entered into a securities purchase agreement with institutional investors to sell 769,490 shares of its common stock at $4.81 per share in a registered direct offering. The offering is expected to close by October 30, 2025, with net proceeds of approximately $3.2 million intended for general corporate purposes, including research and development, administrative costs, and strategic initiatives. The company also entered into a placement agency agreement with Lake Street Capital Markets, LLC, which will receive a 6% cash fee and a warrant to purchase additional shares.

The most recent analyst rating on (EKSO) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on EKSO BIONICS stock, see the EKSO Stock Forecast page.

Ekso Bionics Shows Strong Q3 Recovery and Growth

Ekso Bionics Holdings, Inc., based in San Rafael, California, is a pioneering company in exoskeleton technology, focusing on enhancing human capabilities in both medical and industrial sectors. In its third-quarter 2025 financial report, Ekso Bionics highlighted a notable recovery with a 2% year-over-year revenue growth and a significant 105% increase from the previous quarter, reaching $4.2 million. The company also reported an improved gross margin of 60.3% and a reduced net loss of $1.4 million, marking a 31% improvement from the previous year. Key financial metrics showed a decrease in operating expenses, driven by lower payroll costs due to the Employee Retention Credit, and a strategic focus on high-margin sales. Additionally, Ekso Bionics launched ‘eksoUniversity’, enhancing its educational outreach. Looking ahead, the company is exploring strategic transactions to potentially diversify its business, while continuing to execute its growth strategy. The management remains optimistic about navigating future challenges and opportunities.

Ekso Bionics’ Exoskeleton Study: A Potential Game-Changer for Health and Finance

Ekso Bionics is conducting a clinical study titled ‘Health and Financial Impact on the Use of a Personal Exoskeleton in the Home and Community: a Case Study.’ The study aims to assess the long-term use of a personal overground robotic exoskeleton in individuals with spinal cord injury. Key objectives include evaluating usage patterns, health outcomes such as heart rate and physical activity, and healthcare expenditures over a 12-month period. This research is significant as it explores the potential health and financial benefits of exoskeleton technology in real-world settings.

Ekso Bionics Secures $2M Loan for Working Capital

On September 12, 2025, Ekso Bionics entered into a Secured Promissory Note and Security Agreement with B. Riley Commercial Capital, LLC, securing a $2.0 million loan for working capital and corporate purposes. The agreement includes a 10% interest rate, a maturity date of September 14, 2026, and an option for the lender to convert the loan into equity. This move replaces a previous loan agreement with Banc of California, potentially impacting Ekso Bionics’ financial strategy and stakeholder interests by providing more flexible financing options.

The most recent analyst rating on (EKSO) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on EKSO BIONICS stock, see the EKSO Stock Forecast page.